Jump to content

Web:AXA/FY25/Activity report/summary: Difference between revisions

From Insurer Brain
Browse history interactively
Newer edit →
Content deleted Content added
VisualWikitext
Created page with "== AXA Group — Activity report summary == === December 31, 2025 === === Operating highlights === ==== Governance ==== * Board of Directors proposed the renewal of Thomas Buberl's mandate as director (4-year term) at the 2026 AGM, with intention to reappoint him as CEO. * April 24, 2025 AGM approved renewal of Guillaume Faury and Ramon Fernandez mandates (4 years each) and ratified co-optation of Ewout Steenbergen. Ramon de Oliveira's term ended. * Effective December..."
 
No edit summary
Line 17: Line 17:
==== Significant transactions ====
==== Significant transactions ====


* '''Nobis Group acquisition (completed April 1, 2025):''' Upfront consideration €423m with potential earn-out of up to €55m. Solvency II ratio impact: -1 point in Q2 2025.
* Nobis Group acquisition (completed April 1, 2025): Upfront consideration €423m with potential [[Definition:Earn-out | earn-out]] of up to €55m. [[Definition:Solvency II | Solvency II]] ratio impact: -1 point in Q2 2025.
* '''Sale of AXA Investment Managers to BNP Paribas (completed July 1, 2025):''' Cash proceeds of €5.1bn for AXA IM + €0.3bn for Select = €5.4bn total. One-off net income gain of ca. €2.2bn. Expected annualized reduction in Underlying Earnings of ca. €0.4bn. Long-term partnership established for investment management services. Solvency II ratio impact: ca. +2 points (including associated share buy-back) in Q3 2025.
* Sale of AXA Investment Managers to BNP Paribas (completed July 1, 2025): Cash proceeds of €5.1bn for AXA IM + €0.3bn for Select = €5.4bn total. One-off net income gain of ca. €2.2bn. Expected annualized reduction in [[Definition:Underlying earnings | Underlying Earnings]] of ca. €0.4bn. Long-term partnership established for investment management services. AXA retains full authority over product design, asset allocation and [[Definition:Asset-liability management | asset-liability management]] decisions. Solvency II ratio impact: ca. +2 points (including associated [[Definition:Share buy-back | share buy-back]]) in Q3 2025.
* '''Prima acquisition (completed November 28, 2025):''' Acquired 51% of the leading Italian direct insurance MGA for €0.5bn. Call/put options for remaining stake expected to be exercised in 2029 or 2030. Prima had €1.2bn premiums, ca. 10% Italian retail motor market share, and 90% combined ratio in 2024. Solvency II ratio impact: -3 points at closing + expected -2 points over time from premium recapture.
* Prima acquisition (completed November 28, 2025): Acquired 51% of the leading Italian direct insurance [[Definition:Managing general agent (MGA) | MGA]] for €0.5bn. Call/put options for remaining stake expected to be exercised in 2029 or 2030. Prima had €1.2bn premiums, ca. 10% Italian retail motor market share, and 90% [[Definition:Combined ratio | combined ratio]] in 2024. Expected to strengthen AXA's position in [[Definition:Direct distribution | direct distribution]], which generated €3.5bn in premiums for the Group in 2024. Solvency II ratio impact: -3 points at closing + expected -2 points over time from premium recapture.


==== Capital and debt operations ====
==== Capital and debt operations ====


* '''€1.2bn share buy-back (Feb–May 2025):''' Aligned with capital management policy. Completed May 19, 2025. All shares cancelled.
* €1.2bn share buy-back (Feb–May 2025): Aligned with capital management policy. Completed May 19, 2025. All shares cancelled.
* '''€3.8bn share buy-back (Jul 2025–Jan 2026):''' Offset earnings dilution from AXA IM sale. Completed January 19, 2026. Shares being progressively cancelled.
* €3.8bn share buy-back (Jul 2025–Jan 2026): Offset earnings dilution from AXA IM sale. Completed January 19, 2026. Shares being progressively cancelled.
* '''Shareplan buy-back (Jun–Jun 2025):''' Up to €724.6m to eliminate dilution from Shareplan 2025 and cover stock-based compensation delivery.
* Shareplan buy-back (Jun–Jun 2025): Up to €724.6m to eliminate dilution from Shareplan 2025 and cover stock-based compensation delivery.
* '''Shareplan 2025 (Dec 2025):''' Capital increase of ca. €411m; ca. 13m new shares issued; ca. 42,000 employees in 40 countries (36%+ participation). Post-Shareplan total shares: 2,136,232,264. Employee ownership: 4.82% of capital, 6.61% of voting rights.
* Shareplan 2025 (Dec 2025): [[Definition:Capital increase | Capital increase]] of ca. €411m; ca. 13m new shares issued; ca. 42,000 employees in 40 countries (36%+ participation). Post-Shareplan total shares: 2,136,232,264. Employee ownership: 4.82% of capital, 6.61% of voting rights.
* '''June 2025 debt issuance:''' €1bn RT1 notes (5.750% fixed until Dec 2030; rated BBB+/Baa1(hyb)) + €1bn T2 notes due 2055 (4.375% fixed until Jul 2035; rated A-/A2(hyb)).
* June 2025 debt issuance: €1bn [[Definition:Restricted Tier 1 | Restricted Tier 1]] notes (5.750% fixed until Dec 2030; rated BBB+/Baa1(hyb)) + €1bn [[Definition:Tier 2 | Tier 2]] notes due 2055 (4.375% fixed until Jul 2035; rated A-/A2(hyb)). Both include [[Definition:Loss absorption | loss absorption]] mechanisms under Solvency II.
* '''October 2025 debt issuance:''' €750m RT1 notes (5.125% fixed until Mar 2032; rated BBB+/A3(hyb)) + €750m T2 notes due 2056 (4.125% fixed until Jul 2036; rated A-/A1(hyb)).
* October 2025 debt issuance: €750m Restricted Tier 1 notes (5.125% fixed until Mar 2032; rated BBB+/A3(hyb)) + €750m Tier 2 notes due 2056 (4.125% fixed until Jul 2036; rated A-/A1(hyb)).


=== Events subsequent to December 31, 2025 ===
=== Events subsequent to December 31, 2025 ===


* '''€1.25bn share buy-back approved (Feb 25, 2026):''' Expected to commence as soon as practicable and complete by year-end. All shares to be cancelled.
* €1.25bn share buy-back approved by Board (Feb 25, 2026): Expected to commence as soon as practicable and complete by year-end. All shares to be cancelled.


=== Market environment ===
=== Market environment ===
Line 40: Line 40:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''Stock index performance, FY2025 vs. FY2024 (points)'''
|+ 📈 Stock index performance, FY2025 vs. FY2024 (points)
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Index
! style="background:#eaecf0; text-align:left; width:12em" | Index
Line 95: Line 95:
* US: S&P 500 +16%; tariff-induced volatility peaked in April, then sentiment recovered on resilient growth and easing expectations.
* US: S&P 500 +16%; tariff-induced volatility peaked in April, then sentiment recovered on resilient growth and easing expectations.
* Europe: Eurostoxx 50 +18% on improved growth outlook; CAC 40 +10% (trailing peers due to fiscal uncertainty); FTSE 100 +22% on attractive valuations.
* Europe: Eurostoxx 50 +18% on improved growth outlook; CAC 40 +10% (trailing peers due to fiscal uncertainty); FTSE 100 +22% on attractive valuations.
* Asia: Nikkei +26% driven by AI boom, weaker yen, and U.S.-Japan trade deal; MSCI Emerging +31%.
* Asia: Nikkei +26% driven by global AI boom, weaker yen enhancing export competitiveness, and a U.S.-Japan trade deal; MSCI Emerging +31%.


==== Bond markets ====
==== Bond markets ====
Line 101: Line 101:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''Government bond yields and changes, Dec 2023 to Dec 2025'''
|+ 📈 Government bond yields and changes, Dec 2023 to Dec 2025
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Bond
! style="background:#eaecf0; text-align:left; width:12em" | Bond
Line 156: Line 156:
* Europe: ECB cut deposit rate four times to 2% by year-end. German Bunds rose +49bps (expectations of higher public spending). French OATs +37bps (fiscal discussions). Italian BTPs broadly stable. UK gilts -9bps.
* Europe: ECB cut deposit rate four times to 2% by year-end. German Bunds rose +49bps (expectations of higher public spending). French OATs +37bps (fiscal discussions). Italian BTPs broadly stable. UK gilts -9bps.
* Japan: Sharp +97bps rise to 2.07% as economy exited deflation; BoJ implemented two rate hikes and signaled gradual normalization.
* Japan: Sharp +97bps rise to 2.07% as economy exited deflation; BoJ implemented two rate hikes and signaled gradual normalization.
* Credit spreads tightened: US spreads at tightest since 1998; European spreads compressed across investment grade and high yield.
* [[Definition:Credit spread | Credit spreads]] tightened: US spreads at tightest since 1998; European spreads compressed across both [[Definition:Investment grade | investment grade]] and [[Definition:High yield | high yield]].


==== Exchange rates ====
==== Exchange rates ====
Line 162: Line 162:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''Exchange rates vs. EUR, FY2025'''
|+ 📈 Exchange rates vs. EUR, FY2025
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Currency
! style="background:#eaecf0; text-align:left; width:12em" | Currency
Line 201: Line 201:
==== Insurance market conditions ====
==== Insurance market conditions ====


* '''France:''' Savings market +10% (premiums €192bn); UL +13%, GA +8%; UL share 39%. Total outstanding Life assets reached record €2,107bn (+6%). PER +16% to €20bn. Protection/Health market absorbed medical inflation and regulatory changes via ca. 6% average tariff increase. Nat cat costs to insurers exceeded €10bn in 2025 (vs. €5bn in 2024).
* France: Savings insurance market +10% (premiums €192bn); [[Definition:Unit-linked | Unit-linked]] +13%, [[Definition:General account | General Account]] +8%; UL share 39%. Total outstanding Life insurance assets reached record €2,107bn (+6%). PER (French retirement support plan) +16% to €20bn. [[Definition:Protection (insurance) | Protection]] and complementary Health market absorbed medical inflation and regulatory changes via ca. 6% average tariff increase. [[Definition:Natural catastrophe | Natural catastrophe]] costs to insurers exceeded €10bn in 2025 (vs. €5bn in 2024).
* '''Europe:''' Benign P&C nat cat losses. Profitability favorable post-repricing in recent years. Strong demand for UL savings. Health: aging population, rising claims costs, price increases being implemented.
* Europe: Benign P&C nat cat losses. Profitability favorable post-repricing in recent years. Strong demand for UL savings. Health: aging population, rising claims costs, price increases being implemented. Private health insurers focusing on differentiation through services, vertical integration, and digital transformation.
* '''Japan:''' Life GWP -2.4% (lower foreign-currency single-premium products); UL segment growing. P&C +4% driven by Motor and Fire price increases.
* Japan: Life [[Definition:Gross written premiums | gross written premiums]] -2.4% (lower foreign-currency single-premium products); UL segment growing with new entrants. P&C +4% driven by Motor and Fire price increases.
* '''Hong Kong:''' Life GWP +37%; new business +56% (GA +55%, UL +76%). P&C GWP +9.3%.
* Hong Kong: Life GWP +37%; new business +56% (GA +55%, UL +76%). P&C GWP +9.3%.
* '''United States (Commercial):''' Transition toward more competitive environment; moderating pricing in short-tail lines; persistent pressure in casualty from social inflation; overall profitability remained robust.
* United States (Commercial): Transition toward more competitive environment; moderating pricing in short-tail lines; persistent pressure in casualty from [[Definition:Social inflation | social inflation]]; overall profitability remained robust.
* Industry trends: Insurers investing in AI and data foundations to enhance efficiency and improve pricing and [[Definition:Underwriting | underwriting]] accuracy. Climate change, casualty trends, AI adoption, and demographic shifts generating new insurable assets, risk concentrations, and product requirements.
* '''Emerging markets:''' Asia P&C benefited from Motor (China, Philippines) and Property (Thailand, Philippines). Mexico insurance market +12%; significant legislative change on VAT recoverability in October 2025 impacting Health and P&C profitability. Colombia +8%. Türkiye P&C +43% (30% inflation, volume growth in Motor and Health).
* '''Reinsurance:''' Additional softening projected for 2026 but profitability expected to remain strong (ROE exceeding cost of capital).
* [[Definition:Reinsurance | Reinsurance]]: Additional softening projected for 2026 but profitability expected to remain strong (ROE exceeding cost of capital).
* Emerging markets:
** Asia P&C benefited from Motor (China, Philippines) and Property (Thailand, Philippines). Thailand Life new business +5% driven by [[Definition:Endowment (insurance) | Endowment]] products. Philippines +15% (Endowment and Corporate Solutions). Indonesia: low [[Definition:Persistency | persistency]] in UL, partly offset by new Endowment and Protection launches.
** Mexico insurance market +12%; significant legislative change on VAT recoverability in October 2025 impacting Health and P&C profitability. Colombia +8%. Türkiye P&C +43% (30% inflation, volume growth in Motor and Health).

==== Rankings and market share ====

<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 Market rankings and share by country and business line (%)
|-
! style="background:#eaecf0; text-align:left; width:12em" | Country
! style="background:#eaecf0; width:6em" | P&C ranking
! style="background:#eaecf0; width:6em" | P&C market share (%)
! style="background:#eaecf0; width:6em" | Life ranking
! style="background:#eaecf0; width:6em" | Life market share (%)
! style="background:#eaecf0" | Comments
|-
| style="text-align:left" | France
| 2
| 13.2
| 6
| 7.4
| style="text-align:left" |
* France Assureurs as of Dec 31, 2025
|-
| style="text-align:left" | Switzerland
| 1
| 13.3
| 3
| 10.0
| style="text-align:left" |
* SIA (Swiss Insurance Association) estimates as of Feb 5, 2026
|-
| style="text-align:left" | Germany
| 4
| 5.2
| 7
| 3.4
| style="text-align:left" |
* GDV as of Dec 31, 2024
|-
| style="text-align:left" | Belgium
| 2
| 16.7
| 5
| 6.8
| style="text-align:left" |
* Assuralia based on GWP as of Dec 31, 2024, extrapolated to Dec 31, 2025 using Q3 growth
|-
| style="text-align:left" | United Kingdom
| 6
| 6.0
| —
| —
| style="text-align:left" |
* Association of British Insurers (retail) and GlobalData (commercial)
|-
| style="text-align:left" | Ireland
| 1
| 17.2
| —
| —
| style="text-align:left" |
* Insuranceireland.eu FactFile 2024
|-
| style="text-align:left" | Spain
| 6
| 5.7
| 8
| 3.0
| style="text-align:left" |
* ICEA as of Dec 31, 2025
|-
| style="text-align:left" | Italy
| 4
| 7.2
| 10
| 3.1
| style="text-align:left" |
* ANIA as of Dec 31, 2024
|-
| style="text-align:left" | Japan
| 14
| 0.5
| 10
| 4.1
| style="text-align:left" |
* Disclosed financial reports (excl. KampoLife) for 12 months ended Sep 30, 2025
|-
| style="text-align:left" | Hong Kong
| 2
| 9.2
| 9
| 5.0
| style="text-align:left" |
* Insurance Authority: Life GWP as of Sep 30, 2025; P&C GWP as of Dec 31, 2024
|-
| style="text-align:left" | XL Insurance (US)
| 16
| 1.5
| —
| —
| style="text-align:left" |
* AMBest 2024 (Bestlink US Commercial Group Ranking) as of Dec 31, 2024
|-
| style="text-align:left" | Thailand
| 13
| 2.2
| 5
| 7.2
| style="text-align:left" |
* TGIA and TLAA as of Oct 31, 2025
|-
| style="text-align:left" | Indonesia
| —
| —
| 5
| 7.0
| style="text-align:left" |
* AAJI (Weighted New Business Premiums) as of Sep 30, 2025
|-
| style="text-align:left" | Philippines
| 8
| 3.0
| 6
| 20.0 (TPI) / 27.3 (NBAPE)
| style="text-align:left" |
* Life Insurance Commission: Life TPI and P&C GWP both as of Sep 30, 2025
|-
| style="text-align:left" | China
| —
| 0.3
| —
| —
| style="text-align:left" |
* NFRA as of Dec 31, 2025. P&C ranking and Life ranking/share not disclosed by NFRA
|-
| style="text-align:left" | Mexico
| 4
| 7.9
| 11
| 1.6
| style="text-align:left" |
* AMIS as of Sep 30, 2025
|-
| style="text-align:left" | Brazil
| 11
| 2.7
| —
| —
| style="text-align:left" |
* SUSEP as of Oct 31, 2025
|-
| style="text-align:left" | Colombia
| 3
| 9.4
| 12
| 1.0
| style="text-align:left" |
* Fasecolda as of Nov 30, 2025
|-
| style="text-align:left" | Türkiye
| 4
| 8.3
| —
| —
| style="text-align:left" |
* Insurers association as of Nov 30, 2025
|}
</div>


=== Activity and earnings indicators ===
=== Activity and earnings indicators ===
Line 215: Line 385:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''GWP and other revenues by segment, FY2025 vs. FY2024'''
|+ 📈 GWP and other revenues by segment, FY2025 vs. FY2024
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Metric
! style="background:#eaecf0; text-align:left; width:12em" | Metric
Line 229: Line 399:
| style="background:#f8f9fa" | '''110,316'''
| style="background:#f8f9fa" | '''110,316'''
| style="background:#f8f9fa" | '''+6.5%'''
| style="background:#f8f9fa" | '''+6.5%'''
| style="text-align:left; background:#f8f9fa" | '''Reported: +4.7%. Comparable-basis restatement of €+2.0bn (+1.8pts) from scope (Nobis, Laya, AXA IM sale) and FX (EUR appreciation vs. USD, TRY, MXN, HKD; partly offset by CHF)'''
| style="text-align:left; background:#f8f9fa" |
* '''Reported: +4.7%'''
* '''Comparable-basis restatement of €+2.0bn (+1.8pts) from scope (Nobis, Laya, AXA IM sale) and FX (EUR appreciation vs. USD, TRY, MXN, HKD; partly offset by CHF)'''
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Property & Casualty
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Property & Casualty
Line 237: Line 409:
| +5.2%
| +5.2%
| style="text-align:left" |
| style="text-align:left" |
* ↑ Commercial lines +4%: AXA XL Insurance +3% (Property, Casualty price/volume; Financial lines lower); Asia/Africa/EME-LATAM +13% (Türkiye, Mexico); France +6% (price + volume)
* ↑ Commercial lines +4%: AXA XL Insurance +3% (Property, Casualty price/volume; Financial lines lower); Asia/Africa/EME-LATAM +13% (Türkiye higher avg. premiums, Mexico price/volume); France +6% (price + volume)
* ↑ Personal lines +7%: Europe +5% (price except UK&I Motor softening); Asia/Africa/EME-LATAM +14% (Türkiye); France +9% (volume + Motor price)
* ↑ Personal lines +7%: Europe +5% (price across geographies, except UK&I Motor softening post-2024 repricing); Asia/Africa/EME-LATAM +14% (Türkiye); France +9% (volume growth in all lines, Motor price)
* ↑ AXA XL Reinsurance +8%: alternative capital growth + Casualty price, offset by softening in other lines
* ↑ AXA XL Reinsurance +8%: [[Definition:Alternative capital | alternative capital]] growth + Casualty price, offset by softening in other lines
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Life & Health
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Life & Health
Line 247: Line 419:
| +8.0%
| +8.0%
| style="text-align:left" |
| style="text-align:left" |
* ↑ Life +9%: UL +13% (successful sales across all geographies); GA +4% (France + Italy capital-light product, partly offset by Japan and HK); Protection +11% (HK campaign, Japan and Switzerland)
* ↑ Life +9%: UL +13% (successful sales across all geographies); GA +4% (France + Italy capital-light product, partly offset by non-repeat of Japan [[Definition:Whole life insurance | whole-life]] product and lower HK sales); Protection +11% (HK campaign, Japan and Switzerland)
* ↑ Health +5%: favorable price effects in Group and Individual businesses across most geographies; partly offset by lower volumes
* ↑ Health +5%: favorable price effects in Group and Individual businesses across most geographies; partly offset by lower volumes
|-
|-
Line 269: Line 441:
| 1,701
| 1,701
| n.a.
| n.a.
| style="text-align:left" | FY25 contribution only until July 1, 2025 (sale to BNP Paribas)
| style="text-align:left" |
* FY25 contribution only until July 1, 2025 (sale to BNP Paribas)
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Banking
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Banking
Line 276: Line 449:
| 118
| 118
| -16.2%
| -16.2%
| style="text-align:left" | ↓ Market slowdown + higher funding costs
| style="text-align:left" |
* ↓ Market slowdown + higher funding costs
|-
|-
| style="text-align:left" | Net flows
| style="text-align:left" | [[Definition:Net flows | Net flows]]
| €m
| €m
| 5,397
| 5,397
Line 293: Line 467:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''GWP and other revenues by geography, FY2025 vs. FY2024'''
|+ 📈 GWP and other revenues by geography, FY2025 vs. FY2024
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Geography
! style="background:#eaecf0; text-align:left; width:12em" | Geography
Line 307: Line 481:
| style="background:#f8f9fa" | '''110,316'''
| style="background:#f8f9fa" | '''110,316'''
| style="background:#f8f9fa" | '''+6.5%'''
| style="background:#f8f9fa" | '''+6.5%'''
| style="text-align:left; background:#f8f9fa" | '''Reported: +4.7%'''
| style="text-align:left; background:#f8f9fa" |
* '''Reported: +4.7%'''
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;France
| style="text-align:left" | &nbsp;&nbsp;&nbsp;France
Line 342: Line 517:
| 1,701
| 1,701
| n.m.
| n.m.
| style="text-align:left" | Consolidated until July 1, 2025
| style="text-align:left" |
* Consolidated until July 1, 2025
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Transversal & Other
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Transversal & Other
Line 357: Line 533:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''New business metrics, FY2025 vs. FY2024'''
|+ 📈 New business metrics, FY2025 vs. FY2024
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Metric
! style="background:#eaecf0; text-align:left; width:12em" | Metric
Line 366: Line 542:
! style="background:#eaecf0" | Comments
! style="background:#eaecf0" | Comments
|-
|-
| style="text-align:left" | PVEP
| style="text-align:left" | [[Definition:Present value of expected premiums (PVEP) | PVEP]]
| €m
| €m
| 49,357
| 49,357
Line 376: Line 552:
* Reported: -3%
* Reported: -3%
|-
|-
| style="text-align:left" | NB CSM
| style="text-align:left" | [[Definition:New business contractual service margin | NB CSM]]
| €m
| €m
| 2,199
| 2,199
Line 400: Line 576:
| 4.4%
| 4.4%
| +0.1 pt
| +0.1 pt
| style="text-align:left" | +0.1pt on both reported and comparable basis
| style="text-align:left" |
* +0.1pt on both reported and comparable basis
|}
|}
</div>
</div>
Line 410: Line 587:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''Underlying earnings by business segment, FY2025 vs. FY2024 (€m)'''
|+ 📈 Underlying earnings by business segment, FY2025 vs. FY2024 (€m)
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Metric
! style="background:#eaecf0; text-align:left; width:12em" | Metric
Line 424: Line 601:
| 72,104
| 72,104
| +4%
| +4%
| style="text-align:left" | P&C: 57,656 (vs. 55,898); L&H: 17,416 (vs. 16,207)
| style="text-align:left" |
* P&C: 57,656 (vs. 55,898); L&H: 17,416 (vs. 16,207)
|-
|-
| style="text-align:left" | Short-term technical margin
| style="text-align:left" | Short-term [[Definition:Technical margin | technical margin]]
| €m
| €m
| 5,888
| 5,888
| 5,421
| 5,421
| +9%
| +9%
| style="text-align:left" | P&C: 5,409 (vs. 5,006); L&H: 479 (vs. 415)
| style="text-align:left" |
* P&C: 5,409 (vs. 5,006); L&H: 479 (vs. 415)
|-
|-
| style="text-align:left" | P&C combined ratio
| style="text-align:left" | P&C combined ratio
Line 439: Line 618:
| -0.3 pt
| -0.3 pt
| style="text-align:left" |
| style="text-align:left" |
* ↓ Current-year loss ratio excl. nat cat -0.3pt (Commercial lines -0.5pt, esp. SME/mid-market -0.9pt; Personal lines -0.4pt; AXA XL Insurance stable)
* ↓ Current-year loss ratio excl. nat cat -0.3pt: Commercial lines -0.5pt (SME/mid-market -0.9pt in favorable pricing); Personal lines -0.4pt; AXA XL Insurance stable (+0.1pt)
* ↓ Expense ratio -0.3pt (non-commission efficiency gains)
* ↓ [[Definition:Expense ratio | Expense ratio]] -0.3pt (non-commission efficiency gains)
* ↓ Nat cat charges -0.4pt to 3.4%
* ↓ Nat cat charges -0.4pt to 3.4%
* ↑ Lower prior-year reserve releases +0.7pt (to -1.1%)
* ↑ Lower [[Definition:Prior-year reserve development | prior-year reserve]] releases +0.7pt (to -1.1%)
|-
|-
| style="text-align:left" | L&H short-term combined ratio
| style="text-align:left" | L&H short-term combined ratio
Line 449: Line 628:
| 97.4%
| 97.4%
| -0.2 pt
| -0.2 pt
| style="text-align:left" | Life: 95.4% (vs. 95.5%); Health: 97.9% (vs. 98.1%)
| style="text-align:left" |
* Life: 95.4% (vs. 95.5%); Health: 97.9% (vs. 98.1%)
|-
|-
| style="text-align:left" | CSM release
| style="text-align:left" | [[Definition:Contractual service margin (CSM) | CSM]] release
| €m
| €m
| 2,954
| 2,954
| 2,775
| 2,775
| +6%
| +6%
| style="text-align:left" | ↑ Business growth in reserves + better margins in long-term business
| style="text-align:left" |
* ↑ Business growth in reserves + better margins in long-term business
|-
|-
| style="text-align:left" | Technical experience
| style="text-align:left" | Technical experience
Line 470: Line 651:
| 3,971
| 3,971
| +1%
| +1%
| style="text-align:left" | P&C: 2,631 (vs. 2,559); L&H: 946 (vs. 975); AM: 14 (vs. 35); Holdings: 422 (vs. 402)
| style="text-align:left" |
* P&C: 2,631 (vs. 2,559); L&H: 946 (vs. 975); AM: 14 (vs. 35); Holdings: 422 (vs. 402)
|-
|-
| style="text-align:left" | UE before tax
| style="text-align:left" | UE before tax
Line 477: Line 659:
| 10,700
| 10,700
| +3%
| +3%
| style="text-align:left" | P&C: 8,040 (vs. 7,565); L&H: 4,229 (vs. 4,070); AM: 239 (vs. 546); Holdings: (1,464) vs. (1,482)
| style="text-align:left" |
* P&C: 8,040 (vs. 7,565); L&H: 4,229 (vs. 4,070); AM: 239 (vs. 546); Holdings: (1,464) vs. (1,482)
|-
|-
| style="text-align:left" | Income tax
| style="text-align:left" | Income tax
Line 491: Line 674:
| style="background:#f8f9fa" | '''8,078'''
| style="background:#f8f9fa" | '''8,078'''
| style="background:#f8f9fa" | '''+4%'''
| style="background:#f8f9fa" | '''+4%'''
| style="text-align:left; background:#f8f9fa" | '''Constant FX: +6% (€+469m). P&C +9% (€+501m); L&H +7% (€+219m); AM €-228m; Holdings €-24m'''
| style="text-align:left; background:#f8f9fa" |
* '''Constant FX: +6% (€+469m)'''
* '''P&C +9% (€+501m); L&H +7% (€+219m); AM €-228m; Holdings €-24m'''
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;o/w P&C
| style="text-align:left" | &nbsp;&nbsp;&nbsp;o/w P&C
Line 501: Line 686:
* Constant FX: +9% (€+501m)
* Constant FX: +9% (€+501m)
* ↑ Technical result €+482m (volume growth + margin improvement)
* ↑ Technical result €+482m (volume growth + margin improvement)
* ↑ Financial results €+200m (higher volumes + reinvestment yields on fixed income, partly offset by higher discount unwind)
* ↑ Financial results €+200m (higher volumes + reinvestment yields on fixed income, partly offset by higher discount unwind on [[Definition:Claims reserves | claims reserves]])
* ↓ Higher income taxes €-169m
* ↓ Higher income taxes €-169m
|-
|-
Line 512: Line 697:
* Constant FX: +7% (€+219m)
* Constant FX: +7% (€+219m)
* ↑ Long-term technical result €+156m (CSM release growth)
* ↑ Long-term technical result €+156m (CSM release growth)
* ↑ Short-term technical result €+60m (pricing, underwriting, claims management actions; net of Mexico VAT impact €-114m)
* ↑ Short-term technical result €+60m (pricing, underwriting, [[Definition:Claims management | claims management]] actions; net of Mexico VAT legislative change impact €-114m)
* ↑ Lower income taxes €+65m (favorable tax effects in Germany, France, Mexico)
* ↑ Lower income taxes €+65m (favorable tax effects in Germany, France, Mexico)
* ↓ Lower affiliate contributions, higher minority interests
* ↓ Lower affiliate contributions (notably ICBC-AXA), higher minority interests (improved AXA MPS results)
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;o/w Asset Management
| style="text-align:left" | &nbsp;&nbsp;&nbsp;o/w Asset Management
Line 521: Line 706:
| 402
| 402
| -56%
| -56%
| style="text-align:left" | FY25 includes only H1 2025 contribution (disposal July 1, 2025)
| style="text-align:left" |
* FY25 includes only H1 2025 contribution (disposal July 1, 2025)
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;o/w Holdings
| style="text-align:left" | &nbsp;&nbsp;&nbsp;o/w Holdings
Line 528: Line 714:
| (1,157)
| (1,157)
| -2%
| -2%
| style="text-align:left" | Broadly stable on reported and constant FX basis
| style="text-align:left" |
* Broadly stable on reported and constant FX basis
|-
|-
| style="text-align:left" | CSM stock
| style="text-align:left" | CSM stock
Line 535: Line 722:
| 33,853
| 33,853
| -2%
| -2%
| style="text-align:left" | P&C: 261 (vs. 282); L&H: 32,991 (vs. 33,571)
| style="text-align:left" |
* P&C: 261 (vs. 282); L&H: 32,991 (vs. 33,571)
|}
|}
</div>
</div>
Line 543: Line 731:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''Underlying earnings Group share by geography, FY2025 vs. FY2024 (€m)'''
|+ 📈 Underlying earnings Group share by geography, FY2025 vs. FY2024 (€m)
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Geography
! style="background:#eaecf0; text-align:left; width:12em" | Geography
Line 557: Line 745:
| style="background:#f8f9fa" | '''8,078'''
| style="background:#f8f9fa" | '''8,078'''
| style="background:#f8f9fa" | '''+4%'''
| style="background:#f8f9fa" | '''+4%'''
| style="text-align:left; background:#f8f9fa" | '''Constant FX: +6%'''
| style="text-align:left; background:#f8f9fa" |
* '''Constant FX: +6%'''
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;France
| style="text-align:left" | &nbsp;&nbsp;&nbsp;France
Line 592: Line 781:
| 402
| 402
| -56%
| -56%
| style="text-align:left" | H1 2025 only
| style="text-align:left" |
* H1 2025 only
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Transversal & Other
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Transversal & Other
Line 607: Line 797:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''P&C combined ratio by geography, FY2025 vs. FY2024'''
|+ 📈 P&C combined ratio by geography, FY2025 vs. FY2024
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Geography
! style="background:#eaecf0; text-align:left; width:12em" | Geography
Line 621: Line 811:
| style="background:#f8f9fa" | '''91.0%'''
| style="background:#f8f9fa" | '''91.0%'''
| style="background:#f8f9fa" | '''-0.3 pt'''
| style="background:#f8f9fa" | '''-0.3 pt'''
| style="text-align:left; background:#f8f9fa" | '''On constant FX basis'''
| style="text-align:left; background:#f8f9fa" |
* '''On constant FX basis'''
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;France
| style="text-align:left" | &nbsp;&nbsp;&nbsp;France
Line 671: Line 862:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''P&C combined ratio by line of business, FY2025 vs. FY2024'''
|+ 📈 P&C combined ratio by line of business, FY2025 vs. FY2024
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Line of business
! style="background:#eaecf0; text-align:left; width:12em" | Line of business
Line 692: Line 883:
| 91.1%
| 91.1%
| -0.4 pt
| -0.4 pt
| style="text-align:left" | Revenues: 39,090 (vs. 38,019)
| style="text-align:left" |
* Revenues: €39,090m (vs. €38,019m)
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Personal lines
| style="text-align:left" | &nbsp;&nbsp;&nbsp;Personal lines
Line 699: Line 891:
| 93.9%
| 93.9%
| -1.1 pt
| -1.1 pt
| style="text-align:left" | Revenues: 19,276 (vs. 18,705)
| style="text-align:left" |
* Revenues: €19,276m (vs. €18,705m)
|-
|-
| style="text-align:left" | &nbsp;&nbsp;&nbsp;AXA XL Reinsurance
| style="text-align:left" | &nbsp;&nbsp;&nbsp;AXA XL Reinsurance
Line 706: Line 899:
| 79.7%
| 79.7%
| +1.7 pt
| +1.7 pt
| style="text-align:left" | Revenues: 2,493 (vs. 2,394)
| style="text-align:left" |
* Revenues: €2,493m (vs. €2,394m)
|}
|}
</div>
</div>
Line 714: Line 908:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''Life & Health underlying earnings, FY2025 vs. FY2024 (€m)'''
|+ 📈 Life & Health underlying earnings, FY2025 vs. FY2024 (€m)
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Metric
! style="background:#eaecf0; text-align:left; width:12em" | Metric
Line 728: Line 922:
| 16,207
| 16,207
| +7%
| +7%
| style="text-align:left" | Life: 4,444 (vs. 4,247); Health: 12,972 (vs. 11,960)
| style="text-align:left" |
* Life: 4,444 (vs. 4,247); Health: 12,972 (vs. 11,960)
|-
|-
| style="text-align:left" | Short-term combined ratio
| style="text-align:left" | Short-term combined ratio
Line 735: Line 930:
| 97.4%
| 97.4%
| -0.2 pt
| -0.2 pt
| style="text-align:left" | Life: 95.4% (vs. 95.5%); Health: 97.9% (vs. 98.1%)
| style="text-align:left" |
* Life: 95.4% (vs. 95.5%); Health: 97.9% (vs. 98.1%)
|-
|-
| style="text-align:left" | Short-term technical margin
| style="text-align:left" | Short-term technical margin
Line 742: Line 938:
| 415
| 415
| +15%
| +15%
| style="text-align:left" | Life: 206 (vs. 191); Health: 273 (vs. 224)
| style="text-align:left" |
* Life: 206 (vs. 191); Health: 273 (vs. 224)
|-
|-
| style="text-align:left" | CSM release
| style="text-align:left" | CSM release
Line 749: Line 946:
| 2,775
| 2,775
| +6%
| +6%
| style="text-align:left" | Life: 2,415 (vs. 2,253); Health: 539 (vs. 522)
| style="text-align:left" |
* Life: 2,415 (vs. 2,253); Health: 539 (vs. 522)
|-
|-
| style="text-align:left" | Technical experience
| style="text-align:left" | Technical experience
Line 756: Line 954:
| (95)
| (95)
| -58%
| -58%
| style="text-align:left" | Life: (139) vs. (98); Health: (11) vs. 3
| style="text-align:left" |
* Life: (139) vs. (98); Health: (11) vs. 3
|-
|-
| style="text-align:left" | Financial result
| style="text-align:left" | Financial result
Line 763: Line 962:
| 975
| 975
| -3%
| -3%
| style="text-align:left" | Life: 738 (vs. 799); Health: 209 (vs. 176)
| style="text-align:left" |
* Life: 738 (vs. 799); Health: 209 (vs. 176)
|-
|-
| style="text-align:left" | UE before tax
| style="text-align:left" | UE before tax
Line 770: Line 970:
| 4,070
| 4,070
| +4%
| +4%
| style="text-align:left" | Life: 3,219 (vs. 3,145); Health: 1,010 (vs. 925)
| style="text-align:left" |
* Life: 3,219 (vs. 3,145); Health: 1,010 (vs. 925)
|-
|-
| style="text-align:left" | Income tax
| style="text-align:left" | Income tax
Line 777: Line 978:
| (874)
| (874)
| +8%
| +8%
| style="text-align:left" | Favorable tax effects in Germany, France, Mexico
| style="text-align:left" |
* Favorable tax effects in Germany, France, Mexico
|-
|-
| style="text-align:left; border-top:1px solid #a2a9b1; background:#f8f9fa" | '''UE Group share'''
| style="text-align:left; border-top:1px solid #a2a9b1; background:#f8f9fa" | '''UE Group share'''
Line 784: Line 986:
| style="background:#f8f9fa" | '''3,323'''
| style="background:#f8f9fa" | '''3,323'''
| style="background:#f8f9fa" | '''+5%'''
| style="background:#f8f9fa" | '''+5%'''
| style="text-align:left; background:#f8f9fa" | '''Life: 2,715 (vs. 2,636); Health: 787 (vs. 687). Constant FX: +7% (€+219m)'''
| style="text-align:left; background:#f8f9fa" |
* '''Life: 2,715 (vs. 2,636); Health: 787 (vs. 687)'''
* '''Constant FX: +7% (€+219m)'''
|-
|-
| style="text-align:left" | CSM stock
| style="text-align:left" | CSM stock
Line 791: Line 995:
| 33,571
| 33,571
| -2%
| -2%
| style="text-align:left" | Life: 25,442 (vs. 25,826); Health: 7,550 (vs. 7,744)
| style="text-align:left" |
* Life: 25,442 (vs. 25,826); Health: 7,550 (vs. 7,744)
|}
|}
</div>
</div>
Line 799: Line 1,004:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''Net income Group share bridge, FY2025 vs. FY2024 (€m)'''
|+ 📈 Net income Group share bridge, FY2025 vs. FY2024 (€m)
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Metric
! style="background:#eaecf0; text-align:left; width:12em" | Metric
Line 813: Line 1,018:
| 8,078
| 8,078
| +4%
| +4%
| style="text-align:left" | Constant FX: +6% (€+469m)
| style="text-align:left" |
* Constant FX: +6% (€+469m)
|-
|-
| style="text-align:left" | Net realized capital gains & losses
| style="text-align:left" | Net realized capital gains & losses
Line 820: Line 1,026:
| 195
| 195
| -29%
| -29%
| style="text-align:left" | ↓ €-59m, primarily lower gains on investment properties (France)
| style="text-align:left" |
* ↓ €-59m, primarily lower gains on investment properties (France)
|-
|-
| style="text-align:left" | Fair value of funds & derivatives
| style="text-align:left" | Fair value of funds & derivatives
Line 838: Line 1,045:
| (131)
| (131)
| +34%
| +34%
| style="text-align:left" | ↑ €+40m improvement; mainly AXA XL and Switzerland
| style="text-align:left" |
* ↑ €+40m improvement; mainly AXA XL and Switzerland
|-
|-
| style="text-align:left" | Integration & restructuring costs
| style="text-align:left" | Integration & restructuring costs
Line 855: Line 1,063:
| (99)
| (99)
| n.m.
| n.m.
| style="text-align:left" | ↑ €+2,483m; mainly one-off gain from AXA IM disposal of €2,227m in H2 2025
| style="text-align:left" |
* ↑ €+2,483m; includes one-off gain from AXA IM disposal of €2,227m in H2 2025
|-
|-
| style="text-align:left; border-top:1px solid #a2a9b1; background:#f8f9fa" | '''Net income Group share'''
| style="text-align:left; border-top:1px solid #a2a9b1; background:#f8f9fa" | '''Net income Group share'''
Line 862: Line 1,071:
| style="background:#f8f9fa" | '''7,886'''
| style="background:#f8f9fa" | '''7,886'''
| style="background:#f8f9fa" | '''+24%'''
| style="background:#f8f9fa" | '''+24%'''
| style="text-align:left; background:#f8f9fa" | '''Constant FX: +26% (€+2,069m)'''
| style="text-align:left; background:#f8f9fa" |
* '''Constant FX: +26% (€+2,069m)'''
|}
|}
</div>
</div>
Line 870: Line 1,080:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''Shareholders' equity Group share movement, FY2024 to FY2025 (€m)'''
|+ 📈 Shareholders' equity Group share movement, FY2024 to FY2025 (€m)
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Item
! style="background:#eaecf0; text-align:left; width:12em" | Item
Line 895: Line 1,105:
| €m
| €m
| (4,863)
| (4,863)
| style="text-align:left" | Includes share buy-backs
| style="text-align:left" |
* Includes share buy-backs
|-
|-
| style="text-align:left" | Impact of currency fluctuations
| style="text-align:left" | Impact of currency fluctuations
| €m
| €m
| (3,549)
| (3,549)
| style="text-align:left" | Mainly USD, JPY depreciation against EUR
| style="text-align:left" |
* Mainly USD, JPY depreciation against EUR
|-
|-
| style="text-align:left" | Fair value recorded in shareholders' equity
| style="text-align:left" | Fair value recorded in shareholders' equity
Line 932: Line 1,144:
| style="text-align:left" | —
| style="text-align:left" | —
|-
|-
| style="text-align:left" | Undated subordinated debt (incl. interest)
| style="text-align:left" | [[Definition:Subordinated debt | Undated subordinated debt]] (incl. interest)
| €m
| €m
| (300)
| (300)
Line 945: Line 1,157:
| style="background:#f8f9fa" | '''€m'''
| style="background:#f8f9fa" | '''€m'''
| style="background:#f8f9fa" | '''47,171'''
| style="background:#f8f9fa" | '''47,171'''
| style="text-align:left; background:#f8f9fa" | '''Net decrease of €2,772m driven by share buy-backs (€4,863m paid-in capital) and FX (€-3,549m), partly offset by net income (€+9,797m)'''
| style="text-align:left; background:#f8f9fa" |
* '''Net decrease of €2,772m driven by share buy-backs (€4,863m paid-in capital) and FX (€-3,549m), partly offset by net income (€+9,797m)'''
|}
|}
</div>
</div>
Line 953: Line 1,166:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''Solvency II metrics, FY2025 vs. FY2024'''
|+ 📈 Solvency II metrics, FY2025 vs. FY2024
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Metric
! style="background:#eaecf0; text-align:left; width:12em" | Metric
Line 962: Line 1,175:
! style="background:#eaecf0" | Comments
! style="background:#eaecf0" | Comments
|-
|-
| style="text-align:left" | Eligible Own Funds
| style="text-align:left" | [[Definition:Eligible own funds | Eligible Own Funds]]
| €bn
| €bn
| 56.4
| 56.4
Line 977: Line 1,190:
* ↑ AXA IM sale and associated buy-back: ca. +2pts in Q3 2025
* ↑ AXA IM sale and associated buy-back: ca. +2pts in Q3 2025
* ↓ Nobis acquisition: -1pt in Q2 2025
* ↓ Nobis acquisition: -1pt in Q2 2025
* ↓ Prima acquisition: -3pts at closing; additional -2pts expected over time
* ↓ Prima acquisition: -3pts at closing; additional -2pts expected over time from premium recapture
|}
|}
</div>
</div>
Line 985: Line 1,198:
<div style="overflow-x: auto;">
<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''Earnings per share and return on equity, FY2025 vs. FY2024'''
|+ 📈 Earnings per share and return on equity, FY2025 vs. FY2024
|-
|-
! style="background:#eaecf0; text-align:left; width:12em" | Metric
! style="background:#eaecf0; text-align:left; width:12em" | Metric
Line 999: Line 1,212:
| 2,197
| 2,197
| -3%
| -3%
| style="text-align:left" | ↓ Share buy-backs, partly offset by Shareplan 2025 issuance
| style="text-align:left" |
* ↓ Share buy-backs, partly offset by Shareplan 2025 issuance
|-
|-
| style="text-align:left" | Underlying EPS (fully diluted)
| style="text-align:left" | Underlying EPS (fully diluted)
Line 1,006: Line 1,220:
| 3.59
| 3.59
| +8%
| +8%
| style="text-align:left" | Basic: €3.87 (vs. €3.60)
| style="text-align:left" |
* Basic: €3.87 (vs. €3.60)
|-
|-
| style="text-align:left" | Net income EPS (fully diluted)
| style="text-align:left" | Net income EPS (fully diluted)
Line 1,013: Line 1,228:
| 3.50
| 3.50
| +30%
| +30%
| style="text-align:left" | Basic: €4.54 (vs. €3.51); driven by AXA IM disposal gain
| style="text-align:left" |
* Basic: €4.54 (vs. €3.51)
* Driven by AXA IM disposal gain (one-off)
|-
|-
| style="text-align:left" | Underlying ROE
| style="text-align:left" | Underlying ROE
Line 1,020: Line 1,237:
| 15.2%
| 15.2%
| +0.8 pts
| +0.8 pts
| style="text-align:left" | UE (adj.) €8.2bn / avg. adj. shareholders' equity €51.3bn
| style="text-align:left" |
* UE (adj.) €8.2bn / avg. adj. shareholders' equity €51.3bn
|-
|-
| style="text-align:left" | Net income ROE
| style="text-align:left" | Net income ROE
Line 1,027: Line 1,245:
| 14.8%
| 14.8%
| +3.9 pts
| +3.9 pts
| style="text-align:left" | NI (adj.) €9.6bn / avg. adj. shareholders' equity €51.3bn; includes one-off AXA IM disposal gain
| style="text-align:left" |
* NI (adj.) €9.6bn / avg. adj. shareholders' equity €51.3bn
* Includes one-off AXA IM disposal gain
|-
|-
| style="text-align:left" | Avg. adj. shareholders' equity
| style="text-align:left" | Avg. adj. shareholders' equity
Line 1,034: Line 1,254:
| 51.8
| 51.8
| -1%
| -1%
| style="text-align:left" | Excludes fair value reserves on assets/derivatives, insurance contracts, undated sub debt
| style="text-align:left" |
* Excludes fair value reserves on assets/derivatives, insurance contracts, undated sub debt
|-
| style="text-align:left" | [[Definition:Debt gearing | Debt gearing]]
| —
| —
| —
| —
| style="text-align:left" |
* Not disclosed in this report; refer to 2024 URD for definition
|}
|}
</div>
</div>
Line 1,040: Line 1,269:
=== Outlook ===
=== Outlook ===


* '''Strategic plan context:''' Final year of 2024-2026 "Unlock the Future" plan. Management confident in achieving main financial targets.
* Final year of 2024-2026 "Unlock the Future" plan. Management confident in achieving main financial targets, underpinned by profitable organic growth, scaling technical capabilities, and driving operational efficiency through reinforced cost management.
* '''P&C:''' Pricing remains favorable in Retail and SME/Mid-market; expect continued earn-through of higher pricing and underwriting actions. AXA XL: disciplined cycle management and capital allocation, growing where returns exceed cost of capital. Normalized nat cat load guidance: ca. 4.5 points of combined ratio for 2026.
* P&C: Pricing remains favorable in Retail and SME/Mid-market; expect continued earn-through of higher pricing and underwriting actions. AXA XL: disciplined cycle management and capital allocation, growing where returns exceed cost of capital. Normalized nat cat load guidance: ca. 4.5 points of combined ratio for 2026.
* '''Life & Health:''' Earnings growth expected from short-term business (disciplined pricing and claims management). Long-term business strategy focused on rejuvenating sales, improving persistency, and driving positive net flows to grow CSM over time.
* Life & Health: Earnings growth expected from short-term business (disciplined pricing and claims management). Long-term business strategy focused on rejuvenating sales, improving [[Definition:Persistency | persistency]], and driving positive [[Definition:Net flows | net flows]] to grow CSM over time.
* '''Holdings:''' 2026 results expected at a similar level to 2025.
* Holdings: 2026 results expected at a similar level to 2025.
* '''Financial targets:'''
* Financial targets:
** Underlying EPS growth at the upper end of 6-8% CAGR range for both the 2023-2026E plan period and for 2026.
** Underlying EPS growth at the upper end of 6-8% CAGR range for both the 2023-2026E plan period and for 2026.
** Underlying ROE between 14-16% over 2024-2026E.
** Underlying ROE between 14-16% over 2024-2026E.
** Cumulative organic cash upstream in excess of €21bn for 2024-2026.
** Cumulative organic cash upstream in excess of €21bn for 2024-2026.
* '''Capital management policy:''' 75% total payout ratio (60% dividend payout + 15% annual share buy-backs). Proposed DPS in a given year expected to be at least equal to prior year's DPS.
* Capital management policy: 75% total payout ratio (60% dividend payout + 15% annual share buy-backs). Proposed DPS in a given year expected to be at least equal to prior year's DPS.

=== Market rankings and share ===

<div style="overflow-x: auto;">
{| class="wikitable" style="width:100%; text-align:right"
|+ 📈 '''AXA market rankings and share by country and business line (%)'''
|-
! style="background:#eaecf0; text-align:left; width:12em" | Country
! style="background:#eaecf0; width:6em" | P&C ranking
! style="background:#eaecf0; width:6em" | P&C market share (%)
! style="background:#eaecf0; width:6em" | Life ranking
! style="background:#eaecf0; width:6em" | Life market share (%)
|-
| style="text-align:left" | France
| 2
| 13.2
| 6
| 7.4
|-
| style="text-align:left" | Switzerland
| 1
| 13.3
| 3
| 10.0
|-
| style="text-align:left" | Germany
| 4
| 5.2
| 7
| 3.4
|-
| style="text-align:left" | Belgium
| 2
| 16.7
| 5
| 6.8
|-
| style="text-align:left" | United Kingdom
| 6
| 6.0
| —
| —
|-
| style="text-align:left" | Ireland
| 1
| 17.2
| —
| —
|-
| style="text-align:left" | Spain
| 6
| 5.7
| 8
| 3.0
|-
| style="text-align:left" | Italy
| 4
| 7.2
| 10
| 3.1
|-
| style="text-align:left" | Japan
| 14
| 0.5
| 10
| 4.1
|-
| style="text-align:left" | Hong Kong
| 2
| 9.2
| 9
| 5.0
|-
| style="text-align:left" | XL Insurance (US)
| 16
| 1.5
| —
| —
|-
| style="text-align:left" | Thailand
| 13
| 2.2
| 5
| 7.2
|-
| style="text-align:left" | Indonesia
| —
| —
| 5
| 7.0
|-
| style="text-align:left" | Philippines
| 8
| 3.0
| 6
| 20.0 / 27.3
|-
| style="text-align:left" | China
| —
| 0.3
| —
| —
|-
| style="text-align:left" | Mexico
| 4
| 7.9
| 11
| 1.6
|-
| style="text-align:left" | Brazil
| 11
| 2.7
| —
| —
|-
| style="text-align:left" | Colombia
| 3
| 9.4
| 12
| 1.0
|-
| style="text-align:left" | Türkiye
| 4
| 8.3
| —
| —
|}
</div>

Revision as of 15:00, 21 March 2026

AXA Group — Activity report summary

December 31, 2025

Operating highlights

Governance

  • Board of Directors proposed the renewal of Thomas Buberl's mandate as director (4-year term) at the 2026 AGM, with intention to reappoint him as CEO.
  • April 24, 2025 AGM approved renewal of Guillaume Faury and Ramon Fernandez mandates (4 years each) and ratified co-optation of Ewout Steenbergen. Ramon de Oliveira's term ended.
  • Effective December 1, 2025, leadership changes for next strategic cycle:
    • Guillaume Borie appointed Global Head of Finance, Strategy, Underwriting, Risk and Technology (replacing Frédéric de Courtois).
    • Mathieu Godart appointed CEO of AXA France, joining the Management Committee.
    • Karima Silvent appointed Deputy General Secretary (HR, Audit, Compliance, AXA EssentiALL, GIE AXA).
    • Matthieu Caillat appointed Group Chief Technology & AI Officer and CEO of AXA Group Operations.
  • Ewout Steenbergen appointed Chair of Audit Committee (December 11, 2025), succeeding Isabel Hudson who stepped down December 31, 2025.

Significant transactions

  • Nobis Group acquisition (completed April 1, 2025): Upfront consideration €423m with potential earn-out of up to €55m. Solvency II ratio impact: -1 point in Q2 2025.
  • Sale of AXA Investment Managers to BNP Paribas (completed July 1, 2025): Cash proceeds of €5.1bn for AXA IM + €0.3bn for Select = €5.4bn total. One-off net income gain of ca. €2.2bn. Expected annualized reduction in Underlying Earnings of ca. €0.4bn. Long-term partnership established for investment management services. AXA retains full authority over product design, asset allocation and asset-liability management decisions. Solvency II ratio impact: ca. +2 points (including associated share buy-back) in Q3 2025.
  • Prima acquisition (completed November 28, 2025): Acquired 51% of the leading Italian direct insurance MGA for €0.5bn. Call/put options for remaining stake expected to be exercised in 2029 or 2030. Prima had €1.2bn premiums, ca. 10% Italian retail motor market share, and 90% combined ratio in 2024. Expected to strengthen AXA's position in direct distribution, which generated €3.5bn in premiums for the Group in 2024. Solvency II ratio impact: -3 points at closing + expected -2 points over time from premium recapture.

Capital and debt operations

  • €1.2bn share buy-back (Feb–May 2025): Aligned with capital management policy. Completed May 19, 2025. All shares cancelled.
  • €3.8bn share buy-back (Jul 2025–Jan 2026): Offset earnings dilution from AXA IM sale. Completed January 19, 2026. Shares being progressively cancelled.
  • Shareplan buy-back (Jun–Jun 2025): Up to €724.6m to eliminate dilution from Shareplan 2025 and cover stock-based compensation delivery.
  • Shareplan 2025 (Dec 2025): Capital increase of ca. €411m; ca. 13m new shares issued; ca. 42,000 employees in 40 countries (36%+ participation). Post-Shareplan total shares: 2,136,232,264. Employee ownership: 4.82% of capital, 6.61% of voting rights.
  • June 2025 debt issuance: €1bn Restricted Tier 1 notes (5.750% fixed until Dec 2030; rated BBB+/Baa1(hyb)) + €1bn Tier 2 notes due 2055 (4.375% fixed until Jul 2035; rated A-/A2(hyb)). Both include loss absorption mechanisms under Solvency II.
  • October 2025 debt issuance: €750m Restricted Tier 1 notes (5.125% fixed until Mar 2032; rated BBB+/A3(hyb)) + €750m Tier 2 notes due 2056 (4.125% fixed until Jul 2036; rated A-/A1(hyb)).

Events subsequent to December 31, 2025

  • €1.25bn share buy-back approved by Board (Feb 25, 2026): Expected to commence as soon as practicable and complete by year-end. All shares to be cancelled.

Market environment

Stock markets

📈 Stock index performance, FY2025 vs. FY2024 (points)
Index Dec 31, 2025 YoY change 2025 Dec 31, 2024 YoY change 2024
CAC 40 8,150 +10% 7,381 -2%
Eurostoxx 50 5,791 +18% 4,896 +8%
FTSE 100 9,931 +22% 8,173 +6%
Nikkei 50,339 +26% 39,895 +19%
S&P 500 6,846 +16% 5,882 +23%
MSCI World 4,430 +19% 3,708 +17%
MSCI Emerging 1,404 +31% 1,075 +5%
  • Global equities delivered another strong year despite geopolitical and macro uncertainties. Disinflation trends, clearer monetary signals, and resilient corporate earnings supported markets.
  • US: S&P 500 +16%; tariff-induced volatility peaked in April, then sentiment recovered on resilient growth and easing expectations.
  • Europe: Eurostoxx 50 +18% on improved growth outlook; CAC 40 +10% (trailing peers due to fiscal uncertainty); FTSE 100 +22% on attractive valuations.
  • Asia: Nikkei +26% driven by global AI boom, weaker yen enhancing export competitiveness, and a U.S.-Japan trade deal; MSCI Emerging +31%.

Bond markets

📈 Government bond yields and changes, Dec 2023 to Dec 2025
Bond Dec 31, 2025 YoY change (bps) Dec 31, 2024 YoY change (bps)
10Y French bond 3.56% +37 3.20% +64
10Y German bond 2.86% +49 2.37% +34
10Y Swiss bond 0.32% -1 0.33% -38
10Y Italian bond 3.55% +3 3.52% -18
10Y UK bond 4.48% -9 4.57% +103
10Y Japanese bond 2.07% +97 1.10% +49
10Y US bond 4.17% -40 4.57% +69
  • US: Three Fed rate cuts in Q4; 10Y Treasury fell to 4.17% (-40bps) but long-term yields stayed relatively resilient on fiscal concerns.
  • Europe: ECB cut deposit rate four times to 2% by year-end. German Bunds rose +49bps (expectations of higher public spending). French OATs +37bps (fiscal discussions). Italian BTPs broadly stable. UK gilts -9bps.
  • Japan: Sharp +97bps rise to 2.07% as economy exited deflation; BoJ implemented two rate hikes and signaled gradual normalization.
  • Credit spreads tightened: US spreads at tightest since 1998; European spreads compressed across both investment grade and high yield.

Exchange rates

📈 Exchange rates vs. EUR, FY2025
Currency End of period Dec 31, 2025 EoP change Average 2025 Average change
US Dollar 1.17 +13% 1.13 +5%
British Pound Sterling 0.87 +6% 0.86 +1%
Swiss Franc 0.93 -1% 0.94 -2%
Japanese Yen 184 +13% 169 +3%
  • Sharp USD depreciation driven by faster Fed easing, narrowing rate differentials, and U.S. fiscal/monetary policy concerns. EUR ended at USD 1.17 (+13%).
  • EUR +6% vs. GBP (UK growth softening, BoE more accommodative); broadly stable vs. CHF (-1%); +13% vs. JPY (wide rate differentials despite BoJ normalization).

Insurance market conditions

  • France: Savings insurance market +10% (premiums €192bn); Unit-linked +13%, General Account +8%; UL share 39%. Total outstanding Life insurance assets reached record €2,107bn (+6%). PER (French retirement support plan) +16% to €20bn. Protection and complementary Health market absorbed medical inflation and regulatory changes via ca. 6% average tariff increase. Natural catastrophe costs to insurers exceeded €10bn in 2025 (vs. €5bn in 2024).
  • Europe: Benign P&C nat cat losses. Profitability favorable post-repricing in recent years. Strong demand for UL savings. Health: aging population, rising claims costs, price increases being implemented. Private health insurers focusing on differentiation through services, vertical integration, and digital transformation.
  • Japan: Life gross written premiums -2.4% (lower foreign-currency single-premium products); UL segment growing with new entrants. P&C +4% driven by Motor and Fire price increases.
  • Hong Kong: Life GWP +37%; new business +56% (GA +55%, UL +76%). P&C GWP +9.3%.
  • United States (Commercial): Transition toward more competitive environment; moderating pricing in short-tail lines; persistent pressure in casualty from social inflation; overall profitability remained robust.
  • Industry trends: Insurers investing in AI and data foundations to enhance efficiency and improve pricing and underwriting accuracy. Climate change, casualty trends, AI adoption, and demographic shifts generating new insurable assets, risk concentrations, and product requirements.
  • Reinsurance: Additional softening projected for 2026 but profitability expected to remain strong (ROE exceeding cost of capital).
  • Emerging markets:
    • Asia P&C benefited from Motor (China, Philippines) and Property (Thailand, Philippines). Thailand Life new business +5% driven by Endowment products. Philippines +15% (Endowment and Corporate Solutions). Indonesia: low persistency in UL, partly offset by new Endowment and Protection launches.
    • Mexico insurance market +12%; significant legislative change on VAT recoverability in October 2025 impacting Health and P&C profitability. Colombia +8%. Türkiye P&C +43% (30% inflation, volume growth in Motor and Health).

Rankings and market share

📈 Market rankings and share by country and business line (%)
Country P&C ranking P&C market share (%) Life ranking Life market share (%) Comments
France 2 13.2 6 7.4
  • France Assureurs as of Dec 31, 2025
Switzerland 1 13.3 3 10.0
  • SIA (Swiss Insurance Association) estimates as of Feb 5, 2026
Germany 4 5.2 7 3.4
  • GDV as of Dec 31, 2024
Belgium 2 16.7 5 6.8
  • Assuralia based on GWP as of Dec 31, 2024, extrapolated to Dec 31, 2025 using Q3 growth
United Kingdom 6 6.0 — —
  • Association of British Insurers (retail) and GlobalData (commercial)
Ireland 1 17.2 — —
  • Insuranceireland.eu FactFile 2024
Spain 6 5.7 8 3.0
  • ICEA as of Dec 31, 2025
Italy 4 7.2 10 3.1
  • ANIA as of Dec 31, 2024
Japan 14 0.5 10 4.1
  • Disclosed financial reports (excl. KampoLife) for 12 months ended Sep 30, 2025
Hong Kong 2 9.2 9 5.0
  • Insurance Authority: Life GWP as of Sep 30, 2025; P&C GWP as of Dec 31, 2024
XL Insurance (US) 16 1.5 — —
  • AMBest 2024 (Bestlink US Commercial Group Ranking) as of Dec 31, 2024
Thailand 13 2.2 5 7.2
  • TGIA and TLAA as of Oct 31, 2025
Indonesia — — 5 7.0
  • AAJI (Weighted New Business Premiums) as of Sep 30, 2025
Philippines 8 3.0 6 20.0 (TPI) / 27.3 (NBAPE)
  • Life Insurance Commission: Life TPI and P&C GWP both as of Sep 30, 2025
China — 0.3 — —
  • NFRA as of Dec 31, 2025. P&C ranking and Life ranking/share not disclosed by NFRA
Mexico 4 7.9 11 1.6
  • AMIS as of Sep 30, 2025
Brazil 11 2.7 — —
  • SUSEP as of Oct 31, 2025
Colombia 3 9.4 12 1.0
  • Fasecolda as of Nov 30, 2025
Türkiye 4 8.3 — —
  • Insurers association as of Nov 30, 2025

Activity and earnings indicators

GWP and other revenues

📈 GWP and other revenues by segment, FY2025 vs. FY2024
Metric Unit FY2025 FY2024 Change (comparable) Comments
GWP & other revenues €m 115,524 110,316 +6.5%
  • Reported: +4.7%
  • Comparable-basis restatement of €+2.0bn (+1.8pts) from scope (Nobis, Laya, AXA IM sale) and FX (EUR appreciation vs. USD, TRY, MXN, HKD; partly offset by CHF)
   Property & Casualty €m 58,038 56,514 +5.2%
  • ↑ Commercial lines +4%: AXA XL Insurance +3% (Property, Casualty price/volume; Financial lines lower); Asia/Africa/EME-LATAM +13% (Türkiye higher avg. premiums, Mexico price/volume); France +6% (price + volume)
  • ↑ Personal lines +7%: Europe +5% (price across geographies, except UK&I Motor softening post-2024 repricing); Asia/Africa/EME-LATAM +14% (Türkiye); France +9% (volume growth in all lines, Motor price)
  • ↑ AXA XL Reinsurance +8%: alternative capital growth + Casualty price, offset by softening in other lines
   Life & Health €m 56,512 51,983 +8.0%
  • ↑ Life +9%: UL +13% (successful sales across all geographies); GA +4% (France + Italy capital-light product, partly offset by non-repeat of Japan whole-life product and lower HK sales); Protection +11% (HK campaign, Japan and Switzerland)
  • ↑ Health +5%: favorable price effects in Group and Individual businesses across most geographies; partly offset by lower volumes
      o/w Life €m 37,499 34,497 +9.5% —
      o/w Health €m 19,014 17,486 +5.2% —
   Asset Management €m 875 1,701 n.a.
  • FY25 contribution only until July 1, 2025 (sale to BNP Paribas)
   Banking €m 99 118 -16.2%
  • ↓ Market slowdown + higher funding costs
Net flows €m 5,397 1,483 n.a.
  • ↑ Protection €+4.9bn (HK, Japan, France)
  • ↑ Health €+2.7bn (Germany, Japan, France)
  • ↑ UL €+1.5bn (mainly France)
  • ↓ GA Savings €-3.7bn (GA capital-light inflows €+1.2bn more than offset by traditional GA outflows €-5.0bn)
📈 GWP and other revenues by geography, FY2025 vs. FY2024
Geography Unit FY2025 FY2024 Change (comparable) Comments
GWP & other revenues €m 115,524 110,316 +6.5%
  • Reported: +4.7%
   France €m 30,598 28,996 +5.9% —
   Europe €m 43,005 39,298 +5.6% —
   AXA XL €m 19,277 19,383 +3.8% —
   Asia, Africa & EME-LATAM €m 19,925 19,083 +12.8% —
   AXA IM €m 875 1,701 n.m.
  • Consolidated until July 1, 2025
   Transversal & Other €m 1,844 1,856 -1.3% —

New business performance

📈 New business metrics, FY2025 vs. FY2024
Metric Unit FY2025 FY2024 Change (comparable) Comments
PVEP €m 49,357 50,896 -2.4%
  • Life +1%: higher volumes in HK, France, Switzerland; partly offset by higher interest rate impact on discounting
  • Health -12%: higher interest rate impact on discounting + lower volumes in France (underwriting/pruning actions)
  • Reported: -3%
NB CSM €m 2,199 2,169 +2.7%
  • ↑ Strong Savings and Protection sales
  • ↓ Partly offset by higher interest rate impact on discounting of future profits
  • Reported: +1%
NBV €m 2,233 2,264 -0.2%
  • Stable on comparable basis: NB CSM growth offset by lower contribution from short-term multinational business in France
  • Reported: -1%
NBV margin % 4.5% 4.4% +0.1 pt
  • +0.1pt on both reported and comparable basis

Underlying earnings and net income Group share

Underlying earnings by business segment

📈 Underlying earnings by business segment, FY2025 vs. FY2024 (€m)
Metric Unit FY2025 FY2024 Change (reported) Comments
Short-term revenues €m 75,071 72,104 +4%
  • P&C: 57,656 (vs. 55,898); L&H: 17,416 (vs. 16,207)
Short-term technical margin €m 5,888 5,421 +9%
  • P&C: 5,409 (vs. 5,006); L&H: 479 (vs. 415)
P&C combined ratio % 90.6% 91.0% -0.3 pt
  • ↓ Current-year loss ratio excl. nat cat -0.3pt: Commercial lines -0.5pt (SME/mid-market -0.9pt in favorable pricing); Personal lines -0.4pt; AXA XL Insurance stable (+0.1pt)
  • ↓ Expense ratio -0.3pt (non-commission efficiency gains)
  • ↓ Nat cat charges -0.4pt to 3.4%
  • ↑ Lower prior-year reserve releases +0.7pt (to -1.1%)
L&H short-term combined ratio % 97.2% 97.4% -0.2 pt
  • Life: 95.4% (vs. 95.5%); Health: 97.9% (vs. 98.1%)
CSM release €m 2,954 2,775 +6%
  • ↑ Business growth in reserves + better margins in long-term business
Technical experience €m (150) (95) -58% —
Financial results €m 4,013 3,971 +1%
  • P&C: 2,631 (vs. 2,559); L&H: 946 (vs. 975); AM: 14 (vs. 35); Holdings: 422 (vs. 402)
UE before tax €m 11,044 10,700 +3%
  • P&C: 8,040 (vs. 7,565); L&H: 4,229 (vs. 4,070); AM: 239 (vs. 546); Holdings: (1,464) vs. (1,482)
Income tax €m (2,644) (2,662) -1% —
Underlying earnings Group share €m 8,368 8,078 +4%
  • Constant FX: +6% (€+469m)
  • P&C +9% (€+501m); L&H +7% (€+219m); AM €-228m; Holdings €-24m
   o/w P&C €m 5,872 5,510 +7%
  • Constant FX: +9% (€+501m)
  • ↑ Technical result €+482m (volume growth + margin improvement)
  • ↑ Financial results €+200m (higher volumes + reinvestment yields on fixed income, partly offset by higher discount unwind on claims reserves)
  • ↓ Higher income taxes €-169m
   o/w L&H €m 3,501 3,323 +5%
  • Constant FX: +7% (€+219m)
  • ↑ Long-term technical result €+156m (CSM release growth)
  • ↑ Short-term technical result €+60m (pricing, underwriting, claims management actions; net of Mexico VAT legislative change impact €-114m)
  • ↑ Lower income taxes €+65m (favorable tax effects in Germany, France, Mexico)
  • ↓ Lower affiliate contributions (notably ICBC-AXA), higher minority interests (improved AXA MPS results)
   o/w Asset Management €m 175 402 -56%
  • FY25 includes only H1 2025 contribution (disposal July 1, 2025)
   o/w Holdings €m (1,180) (1,157) -2%
  • Broadly stable on reported and constant FX basis
CSM stock €m 33,253 33,853 -2%
  • P&C: 261 (vs. 282); L&H: 32,991 (vs. 33,571)

Underlying earnings by geography

📈 Underlying earnings Group share by geography, FY2025 vs. FY2024 (€m)
Geography Unit FY2025 FY2024 Change (reported) Comments
Underlying earnings Group share €m 8,368 8,078 +4%
  • Constant FX: +6%
   France €m 2,224 2,071 +7% —
   Europe €m 3,486 3,187 +9% —
   AXA XL €m 1,893 1,820 +4% —
   Asia, Africa & EME-LATAM €m 1,493 1,504 -1% —
   AXA IM €m 175 402 -56%
  • H1 2025 only
   Transversal & Other €m (903) (907) n.m. —

P&C combined ratio by geography

📈 P&C combined ratio by geography, FY2025 vs. FY2024
Geography Unit FY2025 FY2024 Change Comments
Total P&C % 90.6% 91.0% -0.3 pt
  • On constant FX basis
   France % 87.5% 86.8% +0.7 pt —
   Europe % 90.0% 91.0% -1.0 pt —
   AXA XL % 89.7% 90.2% -0.5 pt —
      o/w AXA XL Insurance % 91.0% 91.7% -0.7 pt —
   Asia, Africa & EME-LATAM % 99.2% 99.1% +0.1 pt —
   Transversal & Other % 95.5% 96.2% -0.7 pt —

P&C combined ratio by line of business

📈 P&C combined ratio by line of business, FY2025 vs. FY2024
Line of business Unit FY2025 FY2024 Change Comments
Total P&C % 90.6% 91.0% -0.3 pt —
   Commercial lines % 90.7% 91.1% -0.4 pt
  • Revenues: €39,090m (vs. €38,019m)
   Personal lines % 92.8% 93.9% -1.1 pt
  • Revenues: €19,276m (vs. €18,705m)
   AXA XL Reinsurance % 81.4% 79.7% +1.7 pt
  • Revenues: €2,493m (vs. €2,394m)

Life & Health underlying earnings

📈 Life & Health underlying earnings, FY2025 vs. FY2024 (€m)
Metric Unit FY2025 FY2024 Change (reported) Comments
Short-term revenues €m 17,416 16,207 +7%
  • Life: 4,444 (vs. 4,247); Health: 12,972 (vs. 11,960)
Short-term combined ratio % 97.2% 97.4% -0.2 pt
  • Life: 95.4% (vs. 95.5%); Health: 97.9% (vs. 98.1%)
Short-term technical margin €m 479 415 +15%
  • Life: 206 (vs. 191); Health: 273 (vs. 224)
CSM release €m 2,954 2,775 +6%
  • Life: 2,415 (vs. 2,253); Health: 539 (vs. 522)
Technical experience €m (150) (95) -58%
  • Life: (139) vs. (98); Health: (11) vs. 3
Financial result €m 946 975 -3%
  • Life: 738 (vs. 799); Health: 209 (vs. 176)
UE before tax €m 4,229 4,070 +4%
  • Life: 3,219 (vs. 3,145); Health: 1,010 (vs. 925)
Income tax €m (800) (874) +8%
  • Favorable tax effects in Germany, France, Mexico
UE Group share €m 3,501 3,323 +5%
  • Life: 2,715 (vs. 2,636); Health: 787 (vs. 687)
  • Constant FX: +7% (€+219m)
CSM stock €m 32,991 33,571 -2%
  • Life: 25,442 (vs. 25,826); Health: 7,550 (vs. 7,744)

Net income

📈 Net income Group share bridge, FY2025 vs. FY2024 (€m)
Metric Unit FY2025 FY2024 Change (reported) Comments
Underlying earnings Group share €m 8,368 8,078 +4%
  • Constant FX: +6% (€+469m)
Net realized capital gains & losses €m 138 195 -29%
  • ↓ €-59m, primarily lower gains on investment properties (France)
Fair value of funds & derivatives €m (813) 83 n.m.
  • ↓ €-904m swing driven by:
  • Unfavorable FX on foreign assets/liabilities €-467m (USD depreciation)
  • Unfavorable derivatives €-243m (equity hedging €-120m, IR derivatives €-106m)
  • Unfavorable mutual funds €-102m (Private Equity, Fixed Income; partly offset by Hedge funds)
Amortization of intangibles €m (86) (131) +34%
  • ↑ €+40m improvement; mainly AXA XL and Switzerland
Integration & restructuring costs €m (197) (240) +18%
  • ↑ €+40m improvement
  • Operational efficiency programs €-146m (IT, automation at AXA XL and UK&I)
  • Integration costs €-51m (recent acquisitions)
Exceptional items €m 2,386 (99) n.m.
  • ↑ €+2,483m; includes one-off gain from AXA IM disposal of €2,227m in H2 2025
Net income Group share €m 9,797 7,886 +24%
  • Constant FX: +26% (€+2,069m)

Shareholders' equity Group share

📈 Shareholders' equity Group share movement, FY2024 to FY2025 (€m)
Item Unit Amount Comments
Opening (Dec 31, 2024) €m 49,943 —
Net income for the period €m +9,797 —
Dividends €m (4,629) —
Paid-in capital €m (4,863)
  • Includes share buy-backs
Impact of currency fluctuations €m (3,549)
  • Mainly USD, JPY depreciation against EUR
Fair value recorded in shareholders' equity €m +1,282 —
OCI related to invested assets €m (4,161) —
OCI related to (re)insurance contracts €m +5,443 —
OCI defined benefit plans €m (350) —
Treasury shares €m (97) —
Realized gains on equity through retained earnings €m +111 —
Undated subordinated debt (incl. interest) €m (300) —
Other €m (174) —
Closing (Dec 31, 2025) €m 47,171
  • Net decrease of €2,772m driven by share buy-backs (€4,863m paid-in capital) and FX (€-3,549m), partly offset by net income (€+9,797m)

Solvency information

📈 Solvency II metrics, FY2025 vs. FY2024
Metric Unit FY2025 FY2024 Change Comments
Eligible Own Funds €bn 56.4 55.9 +0.5 —
Solvency II ratio % 224% 216% +8 pts
  • ↑ AXA IM sale and associated buy-back: ca. +2pts in Q3 2025
  • ↓ Nobis acquisition: -1pt in Q2 2025
  • ↓ Prima acquisition: -3pts at closing; additional -2pts expected over time from premium recapture

Shareholder value

📈 Earnings per share and return on equity, FY2025 vs. FY2024
Metric Unit FY2025 FY2024 Change Comments
Weighted avg. shares (fully diluted) m shares 2,124 2,197 -3%
  • ↓ Share buy-backs, partly offset by Shareplan 2025 issuance
Underlying EPS (fully diluted) €/share 3.86 3.59 +8%
  • Basic: €3.87 (vs. €3.60)
Net income EPS (fully diluted) €/share 4.53 3.50 +30%
  • Basic: €4.54 (vs. €3.51)
  • Driven by AXA IM disposal gain (one-off)
Underlying ROE % 16.0% 15.2% +0.8 pts
  • UE (adj.) €8.2bn / avg. adj. shareholders' equity €51.3bn
Net income ROE % 18.8% 14.8% +3.9 pts
  • NI (adj.) €9.6bn / avg. adj. shareholders' equity €51.3bn
  • Includes one-off AXA IM disposal gain
Avg. adj. shareholders' equity €bn 51.3 51.8 -1%
  • Excludes fair value reserves on assets/derivatives, insurance contracts, undated sub debt
Debt gearing — — — —
  • Not disclosed in this report; refer to 2024 URD for definition

Outlook

  • Final year of 2024-2026 "Unlock the Future" plan. Management confident in achieving main financial targets, underpinned by profitable organic growth, scaling technical capabilities, and driving operational efficiency through reinforced cost management.
  • P&C: Pricing remains favorable in Retail and SME/Mid-market; expect continued earn-through of higher pricing and underwriting actions. AXA XL: disciplined cycle management and capital allocation, growing where returns exceed cost of capital. Normalized nat cat load guidance: ca. 4.5 points of combined ratio for 2026.
  • Life & Health: Earnings growth expected from short-term business (disciplined pricing and claims management). Long-term business strategy focused on rejuvenating sales, improving persistency, and driving positive net flows to grow CSM over time.
  • Holdings: 2026 results expected at a similar level to 2025.
  • Financial targets:
    • Underlying EPS growth at the upper end of 6-8% CAGR range for both the 2023-2026E plan period and for 2026.
    • Underlying ROE between 14-16% over 2024-2026E.
    • Cumulative organic cash upstream in excess of €21bn for 2024-2026.
  • Capital management policy: 75% total payout ratio (60% dividend payout + 15% annual share buy-backs). Proposed DPS in a given year expected to be at least equal to prior year's DPS.
Retrieved from "https://www.insurerbrain.com/w/index.php?title=Web:AXA/FY25/Activity_report/summary&oldid=21388"